OI
UTHR icon

Oakbrook Investments’s United Therapeutics UTHR Stock Holding History

Oakbrook Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,900
Closed -$432K – 497
2019
Q4 		$432K Hold
4,900
– – 0.09% 371
2019
Q3 		$391K Buy
+4,900
New +$395K 0.03% 434

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Oakbrook Investments's UTHR Position: Q1 2020 in Review

Oakbrook Investments sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 4,900 shares — an estimated $432K sold.

Oakbrook Investments first reported a position in UTHR in Q3 2019 and held it in 2 quarters. The position peaked at $432K in Q4 2019. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

  • Oakbrook Investments reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oakbrook Investments sold 4,900 United Therapeutics shares in Q1 2020, an estimated $432K.
  • Oakbrook Investments first reported a position in United Therapeutics in Q3 2019 and held it in 2 quarters.
  • Oakbrook Investments's United Therapeutics position peaked at $432K in Q4 2019.
  • 303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Oakbrook Investments's 13F filing for Q1 2020, filed 22 Apr 2020.